http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2601873-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7dd20cb2891e01f0bcfdf5a3390818f6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate | 2021-08-06^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cda998c9c140986eb6c4eb42a8cfd27 |
| publicationDate | 2022-06-15^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2601873-A |
| titleOfInvention | Compositions and methods for preventing and/or inhibiting viral infection and spread |
| abstract | A method of inhibiting coronavirus infection comprising administering interferon to at least a portion of the upper respiratory tract of a person at risk of being exposed to a coronavirus is provided. The interferon may be selected from the group consisting of a Type I interferon, a Type II interferon, a Type III interferon, or combination thereof. The Type I interferon may be interferon-alpha (IFN-α) or interferon-beta (IFN-β). The Type II interferon may be interferon-gamma (IFN-γ). The Type III interferon may be interferon-lambda (IFN-λ). The interferon may be dosed through inhalation of an aerosol, spray, mist, or powder comprising the interferon. The interferon may be administered by means of an aerosol nebuliser. The coronavirus may be SAR-CoV-2 (COVID-19). The method may involve administration of between 1 and 1000 micrograms of interferon. |
| priorityDate | 2020-08-07^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 117 of 117.